Girish S. Kulkarni

Tata Institute of Fundamental Research — India

Medicine · Health Sciences

48h-index9.1kcitations631works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(246), Prostate Cancer Diagnosis and Treatment(157), Prostate Cancer Treatment and Research(152), Urinary and Genital Oncology Studies(130), Cancer, Lipids, and Metabolism(46)

Publications624 total

Efficient neutral-IGM inference from noisy 21-cm forest spectra with latent-space U-Net encoding and <scp>xgboost</scp>
Monthly Notices of the Royal Astronomical Society·2026Open Access
TORRCH: Tomographic reconstruction of the reionization of cosmic hydrogen with Ly$α$ emitters and non-Ly$α$-selected galaxies
arXiv (Cornell University)·2026Open Access
TORRCH: Tomographic reconstruction of the reionization of cosmic hydrogen with Ly$α$ emitters and non-Ly$α$-selected galaxies
ArXiv.org·2026Open Access
E-XQR-30: evidence for an increase in the ionization state of metal absorbers from <i>z</i> ∼ 6 to <i>z</i> ∼ 2
Monthly Notices of the Royal Astronomical Society·2026Open Access
Editorial Commentary
Urology Practice·2026
ECHO21: a tool for modelling global 21-cm signal from dark ages to reionization
RAS Techniques and Instruments·2026Open Access
Development of a reoperative risk prediction model of muscle-invasive upper tract urothelial carcinoma using clinical and radiomic computed tomography features
Canadian Urological Association Journal·2025Open Access
Analysis of upper tract urothelial carcinoma in the Asian population
British Journal of Urology·2025
Re: European Study of Prostate Cancer Screening — 23-Year Follow-up
European Urology·2025
Supplementary Material 1 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial
2025Open Access
Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial
2025Open Access
Risk of metachronous upper tract urothelial carcinoma following non‐muscle‐invasive bladder cancer
British Journal of Urology·2025Open Access
Outcomes Among Rural and Urban Patients With High-Risk Nonmuscle-Invasive Bladder Cancer: Results From the Canadian Bladder Cancer Information System
The Journal of Urology·2025
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
The Lancet·2025· 20 cited
Development and International Evaluation of an Artificial Intelligence–based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non–muscle-invasive Bladder Cancer
European Urology·2025· 3 cited
Comparison of 90-day morbidity and mortality between ileal conduit and orthotopic neobladder following radical cystectomy in a large multi-institutional database
Canadian Urological Association Journal·2025Open Access
Payments to Health Care Professionals and Teaching Hospitals by AI- and Machine Learning–Enabled Medical Device Manufacturers
JAMA·2025Open Access
Association of patient and physician characteristics with androgen‐deprivation‐therapy intensification in patients with de novo hormone‐sensitive metastatic prostate cancer: A population‐based study
Cancer·2025· 2 citedOpen Access
LBA37 A phase II study of avelumab in locally advanced or metastatic penile cancer patients unfit for platinum-based chemotherapy or progressed on or after platinum-based chemotherapy (ALPACA)
Annals of Oncology·2025Open Access
3088P Association of molecular markers with clinical response to TAR-200 in the phase IIb SunRISe-1 trial in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease
Annals of Oncology·2025· 1 citedOpen Access
page 1 of 32Next →

Frequent Co-authors

Neil Fleshner(22), Alexandre R. Zlotta(14), Antonio Finelli(13), Michael A.S. Jewett(11), Bimal Bhindi(9), Zachary Klaassen(9), Peter C. Austin(8), Robert J. Hamilton(8), Christopher J.D. Wallis(7), Ants Toi(7), Ashish M. Kamat(6), Srikala S. Sridhar(6), Theodorus van der Kwast(6), David R. Urbach(6), Wassim Kassouf(6), Thenappan Chandrasekar(6), Hanan Goldberg(6), Thomas Hermanns(5), Peter Chung(5), John Trachtenberg(5)